In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against gram-positive, fastidious gram-negative, and atypical bacteria

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 467-474

  Huband, Michael D ^a   Bradford, Patricia A ^a   Otterson, Linda G ^a   Basarab, Gregory S ^a   Kutschke, Amy C ^a   Giacobbe, Robert A ^a   Patey, Sara A ^a   Alm, Richard A ^a   Johnstone, Michele R ^a   Potter, Marie E ^a   Miller, Paul F ^a   Mueller, John P ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZD 0914; AZITHROMYCIN; AZTREONAM; BETA LACTAM; CEFIXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CIRCULAR DNA; CLINDAMYCIN; COUMAMYCIN A1; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE INHIBITOR; DOUBLE STRANDED DNA; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; METRONIDAZOLE; NOVOBIOCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; RIFAMPICIN; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIINFECTIVE AGENT; BARBITURIC ACID DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR; NUCLEIC ACID SYNTHESIS INHIBITOR; SPIRO COMPOUND; ZOLIFLODACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; CROSS RESISTANCE; DNA CLEAVAGE; DNA SYNTHESIS INHIBITION; DRUG STABILITY; GENE MAPPING; GENE MUTATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; LEGIONELLA PNEUMOPHILA; MINIMUM BACTERICIDAL CONCENTRATION; MUTANT; NEISSERIA GONORRHOEAE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; BACTERIAL PHENOMENA AND FUNCTIONS; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; ATYPICAL BACTERIAL FORMS; BARBITURATES; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; NUCLEIC ACID SYNTHESIS INHIBITORS; SPIRO COMPOUNDS; TOPOISOMERASE II INHIBITORS;

EID: 84920148657     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04124-14     Document Type: Article

References (29)

1. Rossi F, Diaz L, Wollam A, Panesso D, Zhou Y, Rincon S, Narechania A, Xing G, Di Gioia TSR, Doi A, Tran TT, Reyes J, Munita JM, Carvajal LP, Hernandez-Roldan A, Brandao D, vander Heijden IM, Murray BE, Planet PJ, Weinstock GM, Arias C. 2014. Transferable vancomycin resistance in a community-associated MRSA lineage. N Engl J Med 370: 1524-1531. http://dx.doi.org/10.1056/NEJMoa1303359.
2. Nannini E, Murray BE, Arias CA. 2010. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillinresistant Staphylococcus aureus. Curr Opin Pharmacol 10:516-521. http: //dx.doi.org/10.1016/j.coph.2010.06.006.
3. Sánchez García M, De la Torre MA, Morales G, Pelaez B, Tolon MJ, Domingo S, Candel FJ, Andrade R, Arribi A, García N, Martínez Sagasti F, Fereres J, Picazo J. 2010. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 303:2260-2264. http://dx .doi.org/10.1001/jama.2010.757.
4. Ohnishi M, Goparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama S, Kitawaki J, Unemo M. 2011. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 55:3538-3545. http://dx.doi.org/10.1128/AAC.00325-11.
5. Cámara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, Ardanuy C. 2012. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 67:1858-1860. http://dx.doi.org/10.1093/jac/dks162.
6. Talbot GH, Bradley J, Edwards JE, Jr, Gilbert D, Scheld M, Bartlett JG. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42:657-669. http://dx.doi.org/10.1086 /499819.
7. Alm RA, Kutschke A, Otterson LG, Lahiri SD, McLaughlin RE, Lewis LA, Su X, Huband MD, Mueller JP, Gardner H. 2013. Novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae (NG) and Staphylococcus aureus (SA), poster F-1225C. 53rd ICAAC, 10 to 13 September 2013, Denver, CO.
8. Huband MD, Otterson LG, Doig PC, Giacobbe RA, Patey SA, Gowravaram M, Basarab GS, Mueller JP. 2013. Benzisoxazoles: in vitro activity of new bacterial DNA gyrase/topoisomerase IV inhibitors against Grampositive, fastidious Gram-negative, atypical, and anaerobic bacterial isolates, poster F-1220. 53rd ICAAC, 10 to 13 September 2013, Denver, CO.
9. Huband MD, Flamm RK, Rhomberg PR, Mueller JP, Jones RN. 2013. In vitro activity of AZD0914: a new benzisoxazole DNA gyrase inhibitor against Neisseria gonorrhoeae, poster F-1225b. 53rd ICAAC, 10 to 13 September 2013, Denver, CO.
10. Kern G, Basarab GS, Andrews B, Schuck V, Stone G, Kutschke A, Beaudoin ME, San Martin M, Brassil P, Fan J, Mills SD, Doig P. 2011. A DNA gyrase inhibitor with a novel mode of inhibition and in vivo efficacy, poster F1-1840. 51st ICAAC, 17 to 20 September 2011, Chicago, IL.
11. Palmer T, Walkup G, Basarab G, Fan J, Mills SD, Shapiro AB, Sriram S, Andrews B, Gao N, Thresher J, deJonge B, Kern G. 2014. AZD0914 a topoisomerase inhibitor with novelMOIfor treatment of infections with Neisseria gonorrhoeae, poster C-1422. 54th ICAAC, 5 to 9 September 2014, Washington, DC.
12. Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (ed). 2007. Manual of clinical microbiology, 9th ed. ASM Press, American Society for Microbiology, Washington, DC.
13. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M07-A9, ninth edition, volume 32, number 2. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Clinical and Laboratory Standards Institute. 2012. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard M11-A8, eighth edition, volume 27, number 2. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Clinical and Laboratory Standards Institute. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline M26-A, volume 19, number 18. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement M100-S24, volume 34, number 1. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Clinical and Laboratory Standards Institute. 2010. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline M45-A2, volume 19, number 18, 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Edelstein PH, Edelstein MAC, Weidenfeld J, Dorr MB. 1990. In vitro activity of sparfloxacin (CI-978; AT4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 34:2122-2127. http: //dx.doi.org/10.1128/AAC.34.11.2122.
19. Miles AA, Misra SS. 1938. The estimation of the bactericidal power of the blood. J Hyg 38:732-749. http://dx.doi.org/10.1017/S002217240001158X.
20. Lorian V. 2005. Antimicrobial combinations, p 365-440. In Lorian V (ed), Antibiotics in laboratory medicine, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
21. Spangler SK, Bajaksouzian S, Jacobs MR, Appelbaum PC. 2000. Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 Gram-positive and -negative bacteria. Antimicrob Agents Chemother 44:186-189. http://dx.doi.org/10.1128/AAC.44.1.186-189.2000.
22. Pankuch GA, Appelbaum PC. 2005. Postantibiotic effect of DX-619 against 16 Gram-positive organisms. Antimicrob Agents Chemother 49: 3963-3965. http://dx.doi.org/10.1128/AAC.49.9.3963-3965.2005.
23. Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE. 1999. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus. Antimicrob Agents Chemother 43:1845-1855.
24. Schmitz F, Jones ME, Hofmann B, Hansen B, Scheuring S, Luckefahr M, Fluit A, Verhoef J, Hadding U, Heinz H, Kohrer K. 1998. Charac-terization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects on mutation on ciprofloxacin, MIC. Antimicrob Agents Chemother 42:1249-1252.
25. Grossman TH, Bartels DJ, Mullin S, Gross CH, Parsons JD, Liao Y, Grillot A, Stamos D, Olson ER, Charifson PS, Mani N. 2007. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob Agents Chemother 51:657-666. http: //dx.doi.org/10.1128/AAC.00596-06.
26. Stieger M, Angehrn P, Wohlgensinger B, Gmunder H. 1996. GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin. Antimicrob Agents Chemother 40:1060-1062.
27. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA. http://stacks.cdc.gov/view/cdc/20705.
28. Huband MD, Waites KB, Crabb DM, Kohlhoff SA, Hammerschlag MR. 2014. In vitro antibacterial activity of AZD0914 and comparators against Mycoplasma and Chlamydia spp., poster F-265. 54th ICAAC, 5 to 9 September 2014, Washington, DC.
29. Kohlhoff SA, Huband MD, Hammerschlag MR. 6 October 2014. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother http://dx.doi.org/10.1128/AAC.03920-14.